Longboard Pharmaceuticals, Inc. ((LBPH)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Longboard Pharmaceuticals, Inc. is conducting a Phase 3 clinical study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults With Dravet Syndrome.’ The study aims to evaluate the effectiveness and safety of LP352 in managing seizures associated with Dravet Syndrome, a severe form of epilepsy, highlighting its potential significance in improving patient outcomes.
The intervention being tested is LP352, an experimental drug administered orally or via G-tube/PEG tube, designed to reduce seizure frequency in Dravet Syndrome patients. The study also includes a placebo group for comparison.
This interventional study employs a randomized, parallel assignment model with quadruple masking (participant, care provider, investigator, outcomes assessor) to ensure unbiased results. The primary purpose is treatment-focused, aiming to establish LP352’s efficacy and safety.
The study began on October 2, 2024, and is currently recruiting participants. The primary completion and estimated study completion dates have not been specified, but the last update was submitted on July 8, 2025, indicating ongoing progress.
The outcome of this study could significantly impact Longboard Pharmaceuticals’ stock performance and investor sentiment, especially if LP352 proves effective. Success could position Longboard favorably within the competitive landscape of epilepsy treatments, potentially influencing market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.